H.C. Wainwright raised the firm’s price target on Roivant Sciences (ROIV) to $26 from $23 and keeps a Buy rating on the shares. The firm increased revenue estimates for IMVT-1402 in Graves’ disease. Brepocitinib’s Phase 3 win in dermatomyositis is a “game-changer” for Roivant, and the analyst meeting underscored management’s plan to replicate that success, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- JPMorgan extends Roivant top pick status, adds to Analyst Focus List
- Roivant Sciences Highlights Pipeline Progress at Investor Day
- Roivant Sciences highlights pipeline progress at Investor Day
- Moderna price target raised to $18 from $15 at Leerink
- Einhorn’s DME Capital bought PG&E and United Parks in Q3